Skip Navigation

European Heart Journal 1991 12(Supplement E):2-11; doi:10.1093/eurheartj/12.suppl_E.2
Copyright © 1991 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Loscher, T. F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Loscher, T. F.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1991 The European Society of Cardiology

Endothelium-derived nitric oxide: the endogenous nitrovasodilator in the human cardiovascular system

T. F. Loscher

Department of Medicine, Divisions of Cardiology and Clinical Pharmacology and Department of Research, Laboratory of Vascular Research, University Hospital Basel Switzerland

Correspondence: Thomas F. Lüscher, MD, FESC Department of Internal Medicine, University Hospital Basel, CH-4031 Basel, Switzerland

The L-arginine pathway within endothelial cells in the blood vessel wall is the source of production of the endogenous nitrovasodilator, nitric oxide (NO). NO is released under basal conditions and in response to various stimuli such as shear stress and in response to platelet-derived products, coagulation factors and hormones. NO is the mediator of endothelium-dependent relaxation in the circulation and exerts its effects by activating soluble guanylyl cyclase in vascular smooth muscle, which in turn leads to the formation of cyclic guanosine monophosphate (cGMP) and to relaxation. In addition to its effects on vascular smooth muscle, NO is also released abluminally to interact with circulating platelets. Increases in cGMP in platelets are associated with a decreased adhesion and aggregation of cells. Thus, endothelium-derived NO, through its vasodilator and anti-aggregatory properties, prevents vasospasm and thrombus formation in the circulation and thereby helps to maintain blood flow to vital organs such as the heart. Therapeutic nitrates also exert their effects by releasing NO from their molecules and activating soluble guanylyl cyclase. Their effects are particularly pronounced in arteries without endothelium and are reduced in the presence of the basal formation of endothelium-derived NO in intact arteries. The lower basal formation of endothelium-derived NO in veins, as compared to arteries, contributes to the greater sensitivity of venous circulation to nitrates.

Thus, the endothelial L-arginine pathway plays an important protective role in the local regulation of blood flow and through its vasodilator and antiplatelet properties.

Key Words: Cyclic 3' • 5'-guanosine monophosphate • endothelium derived relaxing factor • nitrates • 3-morpholino sydnonimine (SIN-1) • platelets


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.